Player FM - Internet Radio Done Right
Checked 9d ago
추가했습니다 five 년 전
The Uromigos에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 The Uromigos 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
들어볼 가치가 있는 팟캐스트
스폰서 후원
W
Wits & Weights | Fat Loss, Nutrition, & Strength Training for Lifters


Get your free custom nutrition plan (exclusive to podcast listeners) when you join Wits & Weights Physique University for just $27/month -- There was a day when everything we thought we knew about losing weight got turned upside down. For decades, the advice was simple: eat less, move more. But then scientists started asking why weight loss always seemed to get harder over time, and what they discovered changed everything. This landmark Episode 350 explores the paradigm shift that revolutionized our understanding of metabolism, fat loss, and why 95% of people regain lost weight. Main Takeaways: Your body doesn't just passively lose weight, it actively fights back by slowing metabolism and increasing hunger within 2-3 weeks of dieting The shift from moral food judgments to flexible, data-driven nutrition revolutionized sustainable fat loss Three game-changing strategies emerged: macro tracking as a foundation, working with (not against) metabolic adaptation, and strength training as metabolic insurance This scientific revolution changed how we view our bodies, from broken machines needing punishment to intelligent adaptive systems responding to our lifestyle signals Episode Mentioned: Fat Loss vs. Weight Loss Timestamps: 0:01 - The day everything changed about weight loss 4:30 - Why the "eat less, move more" approach failed 8:47 - How your body fights back: the hormone cascade 10:47 - The rise of flexible dieting and evidence-based coaching 12:29 - Key people who changed the game 14:37 - From food restriction to food awareness 19:35 - 3 game-changing strategies from the research Support the show 🎓 Lose fat for good in Physique University, now just $27/mo ( tap here and I’ll create a FREE custom nutrition plan when you join ) 👥 Join our Facebook community for Q&As & support 👋 Ask a question or find me on Instagram 📱 Try MacroFactor 2 weeks free with code WITSANDWEIGHTS (my favorite nutrition app)…
The Uromigos
모두 재생(하지 않음)으로 표시
Manage series 2818403
The Uromigos에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 The Uromigos 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
…
continue reading
435 에피소드
모두 재생(하지 않음)으로 표시
Manage series 2818403
The Uromigos에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 The Uromigos 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
…
continue reading
435 에피소드
모든 에피소드
×T
The Uromigos

1 Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC 48:51
48:51
나중에 재생
나중에 재생
리스트
좋아요
좋아요48:51
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
T
The Uromigos

5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました!!評価はいかに?
T
The Uromigos

1 Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap 27:49
27:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요27:49
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
T
The Uromigos

1 Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials 43:59
43:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요43:59
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
T
The Uromigos

1 Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers? 45:46
45:46
나중에 재생
나중에 재생
리스트
좋아요
좋아요45:46
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
ASCO2025の注目演題を取り上げ解説、ディスカッションしました!
Brian, Tom and Silke discuss their highlights form ASCO 2025
T
The Uromigos

1 Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC) 40:27
40:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요40:27
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
T
The Uromigos

1 Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC 37:22
37:22
나중에 재생
나중에 재생
리스트
좋아요
좋아요37:22
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
T
The Uromigos

1 Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI 19:39
19:39
나중에 재생
나중에 재생
리스트
좋아요
좋아요19:39
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
T
The Uromigos

1 Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session 30:10
30:10
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:10
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
T
The Uromigos

1 Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC 30:49
30:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:49
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
T
The Uromigos

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
T
The Uromigos

1 Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer 34:49
34:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요34:49
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
T
The Uromigos

1 Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer 24:18
24:18
나중에 재생
나중에 재생
리스트
좋아요
좋아요24:18
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
T
The Uromigos

1 Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study 23:49
23:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요23:49
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
T
The Uromigos

Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
日本と海外の違いはあるのか?mHSPCとmCRPCのUromigos Scoreについて激論!!
T
The Uromigos

1 Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas 28:23
28:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요28:23
Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico
T
The Uromigos

1 Episode 413: The Uromigos Score for Advanced Prostate Cancer 37:02
37:02
나중에 재생
나중에 재생
리스트
좋아요
좋아요37:02
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
T
The Uromigos

1 Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC 28:52
28:52
나중에 재생
나중에 재생
리스트
좋아요
좋아요28:52
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
T
The Uromigos

1 Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1 37:20
37:20
나중에 재생
나중에 재생
리스트
좋아요
좋아요37:20
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
T
The Uromigos

1 Episode 411: Live from EIKCS in Amsterdam - RCC Highlights 20:26
20:26
나중에 재생
나중에 재생
리스트
좋아요
좋아요20:26
Viktor Grunwald joins to discuss the new data session from EIKCS
T
The Uromigos

1 Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC 47:27
47:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요47:27
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
T
The Uromigos

1 Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion 33:04
33:04
나중에 재생
나중에 재생
리스트
좋아요
좋아요33:04
今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました!!
T
The Uromigos

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
T
The Uromigos

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
T
The Uromigos

Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
T
The Uromigos

1 Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands 27:09
27:09
나중에 재생
나중에 재생
리스트
좋아요
좋아요27:09
Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.
T
The Uromigos

1 Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands 37:41
37:41
나중에 재생
나중에 재생
리스트
좋아요
좋아요37:41
Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer
T
The Uromigos

1 Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales 25:12
25:12
나중에 재생
나중에 재생
리스트
좋아요
좋아요25:12
Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.
T
The Uromigos

1 Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands 30:29
30:29
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:29
Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.
T
The Uromigos

Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.
T
The Uromigos

1 Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers? 36:44
36:44
나중에 재생
나중에 재생
리스트
좋아요
좋아요36:44
Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.
T
The Uromigos

1 Episode 398: Reflections on the Felix Feng Symposium at ASCO GU 32:05
32:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요32:05
Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.
T
The Uromigos

Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
T
The Uromigos

ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました!!
T
The Uromigos

1 Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025 30:27
30:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:27
Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)
Silke joins Tom and Brian to discuss highlights form ASCO GU 2025
T
The Uromigos

1 Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC 30:09
30:09
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:09
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
T
The Uromigos

1 Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214 23:28
23:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요23:28
Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
T
The Uromigos

1 Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update 30:03
30:03
나중에 재생
나중에 재생
리스트
좋아요
좋아요30:03
Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data
T
The Uromigos

1 Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer 25:28
25:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요25:28
Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
T
The Uromigos

1 Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results 27:07
27:07
나중에 재생
나중에 재생
리스트
좋아요
좋아요27:07
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
T
The Uromigos

1 Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes 28:23
28:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요28:23
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
T
The Uromigos

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
T
The Uromigos

1 Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC 33:11
33:11
나중에 재생
나중에 재생
리스트
좋아요
좋아요33:11
David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
T
The Uromigos

残念ながらNegative StudyとなったTROPICs-04についてUromigos Japanの3人が忖度なしに、その原因や理由について考察をします!!
T
The Uromigos

1 Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade 40:05
40:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요40:05
Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
T
The Uromigos

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待!
T
The Uromigos

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
T
The Uromigos

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
T
The Uromigos

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.